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Mitochondrial DNA depletion syndromes (MTDPS) are a group of rare genetic
disorders caused by defects in multiple genes involved in mitochondrial DNA (mtDNA)
maintenance. Among those, FBXL4mutations result in the encephalomyopathic mtDNA
depletion syndrome 13 (MTDPS13; OMIM #615471), which commonly presents as a
combination of failure to thrive, neurodevelopmental delays, encephalopathy, hypotonia,
and persistent lactic acidosis. We report here the case of a Lebanese infant presenting to
us with profound neurodevelopmental delays, generalized hypotonia, facial dysmorphic
features, and extreme emaciation. Whole-exome sequencing (WES) showed the girl
as having MTDPS13 with an underlying FBXL4 missense mutation that has been
previously reported only twice in unrelated individuals (c.1303C > T). Comprehensive
literature search marked our patient as being the 94th case of MTDPS13 reported to
date worldwide, and the first from Lebanon. We include at the end of this report a
comprehensive mutation review table of all the pathological FBXL4mutations reported in
the literature, using it to highlight, for the first time, a possible founder effect of Arab origins
to the disorder, beingmost prevalent in patients of Arab descent as shown in our mutation
table. Finally, we provide a direct comparison of the disorder’s clinical manifestations
across two unrelated patients harboring the same disease-causing mutation as our
patient, emphasizing the remarkable variability in genotype-to-phenotype correlation
characteristic of the disease.
Keywords: mitochondria, mitochondrial diseases, mitochondrial fusion, mitochondrial DNA (mtDNA), FBXL4,
pediatric genetics, rare diseases, genetic mutations
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INTRODUCTION
Mitochondrial DNA (mtDNA) synthesis is an intricate and
complex process requiring specific stoichiometric proportions
of replicative enzymes and a tightly regulated pool of
mitochondrial nucleotides (El-Hattab et al., 2017b). While
the latter is maintained through the concerted actions of
carrier-mediated transport of nucleotides from the cytosol into
the mitochondria and a specialized nucleotide salvage pathway
withinmitochondria, the former obligates thatmitochondria fuse
and exchange their contents, including replisome components
(Chen et al., 2010; El-Hattab et al., 2017b; Viscomi and Zeviani,
2017). Thus, mutations affecting genes integral to any of
these processes, including mitochondrial fusion, can result in
impaired mtDNA synthesis and subsequently, mtDNA depletion
(El-Hattab et al., 2017b; Viscomi and Zeviani, 2017).
Among the proteins recently reported as mutated in a subset
of patients with mtDNA depletion syndromes is the F-box and
leucine-rich repeat 4 protein (FBXL4) (Bonnen et al., 2013;
Huemer et al., 2015; Almannai et al., 2017; Dai et al., 2017),
an orphan member of the F-box family of proteins that are
key components of the Skp1-Cullin-F-box (SCF) ubiquitin ligase
complex (Bai et al., 1996), and thus, play a role in ubiquitination
(Cenciarelli et al., 1999; Winston et al., 1999). The protein has
also been shown to possess a mitochondrial-translocation signal
that targets its trafficking into the inter-membrane space of
mitochondria (Bonnen et al., 2013; Gai et al., 2013). Despite
previous studies showing a reduced mtDNA content, lower
steady-state levels of the mtDNA-encoded respiratory chain
enzyme subunits, and a fragmented mitochondrial network with
an overall reduced mitochondrial mass in FBXL4-deficient cells
(Bonnen et al., 2013; Gai et al., 2013; Huemer et al., 2015), the
precise role of FBXL4 remains unknown.
Encephalomyopathic mtDNA depletion syndrome 13
(MTDPS13; OMIM # 615471) is an extremely rare autosomal
recessive disorder arising from bi-allelic mutations in the FBXL4
gene (MIM 605654). Clinically, MTDPS13 typically presents
with failure to thrive, remarkable neurodevelopmental delays,
encephalopathy, cerebral atrophy, generalized hypotonia, and
persistent lactic acidosis (Bonnen et al., 2013; Gai et al., 2013;
Huemer et al., 2015; Almannai et al., 2017). Additionally,
biochemical and molecular testing on samples obtained from
MTDPS13-affected subjects show mtDNA depletion, abnormal
mitochondrial morphology, and electron transfer chain defects
(Bonnen et al., 2013; Gai et al., 2013; Huemer et al., 2015).
To our best knowledge, only 93 cases of FBXL4 deficiency
have been reported to date in the literature (Shamseldin et al.,
2012; Bonnen et al., 2013; Gai et al., 2013; Huemer et al., 2015;
Wortmann et al., 2015; Antoun et al., 2016; Barøy et al., 2016;
Morton et al., 2016; Pronicka et al., 2016; van Rij et al., 2016;
Dai et al., 2017; El-Hattab et al., 2017a), with no prior attempts
of elucidating any potential ethnic correlations.
Thus, we decided to report herein the case of a 9 month-
old girl of Lebanese-Arab origins who presented to us with
Abbreviations: mtDNA, Mitochondrial DNA; FBXL4, F-box and leucine-rich
repeat 4 protein; WES, Whole-exome sequencing; CRP, C-reactive peptide.
pervasive neurodevelopmental delays and generalized hypotonia,
first noted by her parents at the age of 3 months. After a
series of investigations, the girl was diagnosed with FBXL4-
related MTDPS13, resulting from a homozygous nonsense
mutation [NM_012160.4 (FBXL4): c.1303C>T (p.Arg435∗)]
acquired from her carrier parents. Her mutation has only been
reported twice within the literature before (OMIM: 605654.0002)
(Bonnen et al., 2013; Huemer et al., 2015), yet displays a vast
genotype-phenotype variability when comparing her to the two
other cases. We also provide a comprehensive summary of all
FBXL4-deficient cases reported to date in the literature, including
our case, to act as a future mutation reference table for updates
and association studies.
BACKGROUND
A 9 month-old girl of Lebanese-Arab origins was brought to
us by her parents for evaluation of her remarkably delayed
acquisition of age-appropriate neurodevelopmental milestones,
along with generalized hypotonia, first noticed at the age of 3
months. The parents are first-degree cousins with an extensive
history of consanguinity in either side of the family. However,
both family histories are negative for any neurological disorders
or developmental abnormalities. The proband was born at
term via an elective C-section, after a non-remarkable prenatal
history. However, her birth weight, height, and occiput-frontal
circumference were all at the 5th percentiles (2.4 kg, 46 and
33 cm, respectively).
Newborn screening was non-revealing and she had an
uneventful postnatal course. She was exclusively breast-fed
until the age of 3 months when she contracted pneumonia
that necessitated and intravenous antibiotics for 10 days.
However, she gradually recovered afterwards with no further
complications. Nonetheless, since discharge and up until the age
of 6 months, her parents had regularly noticed a persistent head
drop that failed to catch up by 6 months of age, along with an
inability to roll-over or sit supported by that time. However,
the daughter was never evaluated by a pediatrician since
birth.
On inspection, the girl exhibits profound facial dysmorphic
features, including a bossing forehead, supraorbital ridge
protuberance, long and dark eyelashes, thick and fuzzy
eyebrows with remarkable hirsutism, and a smooth and long
philtrum.
Physical examination revealed a distended round abdomen
with an otherwise paradoxical emaciated habitus. No signs of
dehydration were noted, and themother confirmed adequate oral
intake. Her weight was 3.2 kg (−6 SD below the mean) and her
height was 60 cm (−3.5 SD below themean). She exhibited severe
microcephaly with a head circumference of 39 cm (−4 SD below
the mean).
History excluded dysphagia, feeding difficulties, and any
gastrointestinal manifestations that can explain her reduced
weight. However, they reported a poor development in her
mastication skills, necessitating her maintenance on a mashed
diet to avoid any choking or aspiration.
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Neurologically, the girl was overall hypotonic with diffuse
muscle wasting, yet no dystonic features. Her Denver
developmental scale II (DDS-II) assessment confirmed her
inability to roll-over or sit with support as reported by the
mother, and additionally highlighted deficits in pointing at
or reaching out to objects of interest. Of note however, age-
appropriate social behavior and skills were normal, and she
was able to recognize the smiles of her parents and coo to
them. She displayed no strabismus or nystagmus, and tracked
movement normally. Thus, her developmental age at the time
was estimated as being 3–4 months, profoundly delayed relative
to her chronological age (i.e., 9 months).
Basic laboratory studies showed severe anemia (hemoglobin
6.82g/dL [N: 11.1–14.1), mild leukopenia (4,710 white blood
cells/mm3 [N: 5,000–10,000]), thrombocytosis (617,000
platelets/uL [N: 150,000–400,000]), hypoalbuminemia (29 [N:
36–53]), normal blood urea nitrogen level (15 mg/dL [N: 8–25]),
mild lactic acidosis (3.5 mmol/L [N: < 2.2]), and markedly
elevated C-reactive peptide level (CRP; 251 mg/L [N: < 2.5]). Of
interest, her labs showed no hyperammonemia (28 umol/L [N:
< 50]) or ketosis. Urinalysis and chest X-ray were normal, and
her plasma and urine amino and organic acid levels were within
reference range.
Ophthalmological evaluation of extraocular movements and
gaze, as well as funduscopic (retinal) examination were all
normal. Otoacoustic emission testing, echocardiography, and
abdominal ultrasound were normal as well. However, brain
magnetic resonance imaging (MRI) showed bilateral fronto-
temporal atrophy and ventricular enlargement, in the absence
of hydrocephalus, intracranial calcifications, or any hypo-intense
lesions.
At this point, we sought whole-exome sequencing (WES)
for the trio, only to discover that the proband is carrying
a homozygous non-sense mutation in FBXL4 [NM_012160.4:
c.1303C>T (p.Arg435∗)], diagnosing her consequently with
FBXL4-related MTDPS13. The parents were both carriers of that
mutation.
However, our patient was lost to follow up after her diagnosis
at the age of 9 months, despite several attempts to have her
parents return for follow up. However, we did reach out to the
family afterwards to check on the girl’s status at the time, to
learn that she was 2 years and 8 months old back then, with a
persistence of her inability to walk or talk. At that instance, we
obtained parental written consent to have their daughter’s rare
case reported.
DISCUSSION
To our best knowledge, our patient constitutes the 94th case
of FBXL4-related encephalomyopathic MTDPS13 reported to
date in the literature (Supplementary Table; Shamseldin et al.,
2012; Bonnen et al., 2013; Gai et al., 2013; Huemer et al.,
2015; Wortmann et al., 2015; Antoun et al., 2016; Barøy
et al., 2016; Morton et al., 2016; Pronicka et al., 2016; van Rij
et al., 2016; Dai et al., 2017; El-Hattab et al., 2017a). Despite
exhibiting several of the “typical” manifestations reported
previously in MTDPS13 such as hypotonia, encephalopathy
with brain atrophy, lactic acidosis, and stunted growth
(Bonnen et al., 2013; Gai et al., 2013; Huemer et al., 2015;
Almannai et al., 2017; El-Hattab et al., 2017a), our patient
also had two rather “unusual” findings worth highlighting:
severe anemia, and a normal blood ammonia level (i.e., absence
of hyperammonemia) (Almannai et al., 2017). Nonetheless,
the absence of feeding problems, discernible GI (normal
and regular bowel movements, negative stool culture, and
normal ultrasound) or liver pathology (no jaundice, normal
liver enzymes, and only borderline low albumin), and lack
of ketones in urine, along with a normal MCV, rule out
nutritional deficiency or underfeeding as the likely etiologies
of her severe anemia. In this case, one may argue that her
anemia is just another example of the genotype-phenotype
variability characteristic of the disorder, where in her case
there is an involvement of her bone marrow stem cell
population in the disease, taking into consideration her other
aforementioned hematological abnormalities (leukopenia and
thrombocytosis).This however remains only a hypothetical
claim, with the precise reason for her severe anemia remaining
unclear.
Her mutation [c.1303C>T (p.Arg435∗)] has been previously
identified elsewhere only twice, in two unrelated individuals in
2013 (Bonnen et al., 2013) and 2015 (Huemer et al., 2015). Of
interest, when we sought the individual patient data from the
lead authors of those two studies, we discovered that these two
other patients sharing our patient’s mutation were also born to
consanguineous Arab parents.
To date, a total of 47 pathogenic mutations have been
identified in the FBXL4 locus (Table 1), the majority of which are
missense (24/47; 51%) and non-sense mutations (10/47; 21%).
Only a minute fraction are actually frameshift (7/47; 15%) or
splice-site mutations (6/47; 13%).
Of noteworthy however, among all FBXL4 genotypes reported
to date in the literature (Table 1; n = 49), four genotypes
particularly appear to be the most prevalent, affecting more
than one-third of all FBXL4 deficiency patients reported to
date (36 out of 94 i.e., 38%). Among those, the homozygous
[c.1698A>G (p.Ile566Met)] genotype arising from a missense
mutation that has only been recently identified by El Hattab
et al. in 14 of their 37 patients, ranks highest in prevalence,
affecting nearly 15% (14/94) of all FBXL4 deficiency patients
reported to date (El-Hattab et al., 2017a). In contrast, the second
and third most common genotypes were both the result of
homozygous non-sense (i.e., null) mutations ([c.1555C>T (p.
Gln519∗)] and [c.1303C>T (p. Arg435∗)] ,respectively), detected
in 11% (10/94) and 7% (7/94), respectively, of all listed FBXL4
deficiency patients. Finally, the fourth most common genotype
apparently is the result of a homozygous missense mutation
[c.1703G>C (p.Gly568Ala)] that has been seen in 5 of the 94
patients identified to date (i.e., 5%).
Of further interest and through reviewing patient
demographic data, the four aforementioned genotypes affecting
more than a third of all identified FBXL4 deficiency patients were
all actually identified in Arab patients exclusively, suggesting
a possibly higher prevalence of the condition among Arabs
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compared to other ethnic groups. However, the reasons for
this remain unknown at the moment. High consanguinity
rates characteristic of this ethnic group may partially but not
completely account for this observation (Inhorn et al., 2009;
Tadmouri et al., 2009), and/or alternatively, Arabs may have
higher carrier-status rates of FBXL4 mutations compared to
other ethnicities, similar to the higher Huntington’s disease (i.e.,
CAG triplet repeat expansion) carrier rates among Europeans
compared to other populations as an analogy (Orth et al., 2010).
Alternatively, a founder’s effect for the disorder among Arabic
populations can be a reasonable argument when considering
that the disorder’s four predominant genotypes, accounting
for more than one-third of the patients reported thus far with
the disorder globally, were seen exclusively in patients of Arab
descent. However, the disorder itself as summarized in Table 1
has been reported in various ethnic groups as well, though not
as apparently predominant as in Arabs. These explanations
however remain only hypothetical suggestions, with the true
reasons behind this observation being unknown at the moment,
yet a worthwhile target of future investigation.
Despite her poor neurodevelopmental outcome, our patient
was still alive when we last heard from the family at the age of
2 years and 8 months, unlike the patient reported by Bonnen
et al. (boy; S2) who had the same genotype yet passed away at
the age of 4 months (Bonnen et al., 2013). In fact, the latter
had three siblings and one cousin with the same genotype,
presenting at a much earlier age compared to our patient, with
all of them passing away shortly after birth (Bonnen et al., 2013).
However, no information is available on the fate of the other
patient carrying the same mutation and reported by Huemer
et al. (patient 13), due to loss of follow up (Huemer et al.,
2015).
Table 2 compares the presentations of all three patients
mentioned above, highlighting the broad phenotypic spectrum
of the disorder among patients with identical genotypes. In
particular, the age at onset of symptoms was remarkably
different, ranging from immediately postpartum (patient 13)
(Huemer et al., 2015) to 3 months of age in the case of our
patient, and an intermediary age of symptom onset for the
third patient (S2) who first developed symptoms within the
first month after birth (Bonnen et al., 2013). Moreover, our
patient did not have cardiomyopathy and only had a mildly
elevated lactic acid level (3.5 mmol/L) compared to the two
other patients (S2 and patient 13) who both had discernible
cardiomyopathy and remarkably high (and equal) levels of lactic
acidosis (18 mmol/L). This possibly suggests an “attenuated”
version of the disorder in our patient compared to the two
other patients reported elsewhere, given her longer survival
and lower comorbidities. Interestingly, while both, our patient
and patient 13 had no cataracts at birth, S2 had bilateral
cataracts with optic atrophy. Additionally, while our patient
and S2 both displayed the disorder’s “typical” facial dysmorphic
features, patient 13 showed no facial dysmorphism. This clearly
demonstrates the non-true-breeding nature of FBXL4-related
MTDPS13, which can clearly present with a broad array of
phenotypic characteristics, even amongst patients with the same
genotypes.
Finally, based on the biochemical and cellular alterations
seen with pathological FBXL4 mutations, FBXL4 protein is
now believed to play a key role in oxidative phosphorylation
and mitochondrial dynamics, primarily mitochondrial fusion,
a process key for mtDNA maintenance (Bonnen et al., 2013;
Gai et al., 2013; Huemer et al., 2015; El-Hattab et al.,
2017a). Additionally, with recent findings that somatic FBXL4
TABLE 2 | A direct comparison of our patient’s manifestations to those of the two other patients reported elsewhere with an identical FBXL4 genotype.
Our patient Bonnen et al. (2013) (S2) Huemer et al. (2015) (Patient 13)
†
Sex Female Male Male
Age of symptom
onset
3 months Before 1 month At birth (day 0)
Age at
presentation
9 months 1 month 1 day
Birthweight (kg) 2.4 2.3 Unknown
Hypotonia Severe Severe Severe
Cataracts Absent Present, with optic atrophy Absent
Cardiac anomalies None Cardiomyopathy Cardiomyopathy
Brain MRI findings Bilateral temporal
and frontal atrophy
with non-
hydrocephalus
ventriculomegaly.
Prominence of the Cisterna
Magna, with an abnormal
appearance of the dorsal
brainstem and posterior
limb of the internal capsule.
Cerebellar hypoplasia
Lactic acid levels
(mmol/L)
3.5 18 18
Ammonia levels Non-elevated Non-elevated Unknown
Age at death Lost to follow-up ∧ 4 months Lost to follow-up
†
This boy did not have any facial dysmorphic features.
∧Patient was still alive at the age of 2 years and 8 months, after which she was lost to follow-up.
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mutations increase the likelihood of prostate cancer metastasis
to bone (Stankiewicz et al., 2017), and modify the circadian
GABA-ergic cyclical alteration in lateral ventral nuclei of
drosophila (Li et al., 2017), suggest not only a potential role
for FBXL4 in cell migration, but possibly in the sleep-wake
cycle as well, respectively. Nonetheless, the precise function
of FBXL4 remains poorly defined and a subject of further
research.
CONCLUDING REMARKS
We hope our case sheds light on the higher prevalence of
FBXL4-related MTDPS13 among patients of Arabic ethnicity,
while highlighting the disease’ characteristically remarkable
genotype-phenotype variability nature. We hope that this report
also serves to raise awareness among pediatric neurologists
and medical geneticists of the rare yet disabling nature
of mtDNA maintenance defects such as FBXL4-deficiencies,
and therefore, the importance of pursuing further research
in the field to better characterize the exact function(s) of
FBXL4. Such an understanding would allow better identification
of possible targets for future therapeutic intervention that
would aim at completely replacing the defective protein,
or alternatively, augmenting any residual activity it may
possess.
ETHICS STATEMENT
This study was exempt from ethical approval procedures being
a case report of a single patient whose parents have voluntarily
provided oral consent to participate in the study, and written
consent to have her case published. As per the Institutional
Review Board (IRB) of the AmericanUniversity of Beirut, no pre-
approval is required for the publication of a case report of a single
patient.
AUTHOR CONTRIBUTIONS
RB was the third-year medical student interviewing the patient’s
parents during their first visit and performing the initial physical
examination of the patient that was replicated by CA (the fellow
in pediatric neurology) for confirmation. RB and CA finalized the
case with RS, the pediatric neurologist, who then requested the
performed tests and imaging studies. RB, CA, and RS met and
reviewed the labs, imaging, and WES results of the patient, and
RB and RS obtained written informed consent from the parents
to have their daughter’s case reported. RB then invited AE-H, PB,
and MH, the lead authors of the previous “foundational” studies
on FBXL4 deficiency to join the authorship team. PB and MH
provided us with unpublished data on their previously reported
patients with the same mutation as ours. AE-H also provided us
with crude data from his latest review on FBXL4 deficiency and
provided us with guidance on drafting the introduction and the
remainder of the case description. RB drafted the preliminary
copy of the entire manuscript which was subsequently revised,
edited, and approved by all authors.
FUNDING
All requested laboratory and imaging studies, including WES,
were covered by the Department of Pediatrics at the American
University of Beirut Medical Center. PB is supported by the
National Institute of Neurological Disorders and Stroke (NINDS)
at the National Institutes of Health under the award number
[R01NS083726].
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fgene.
2019.00039/full#supplementary-material
REFERENCES
Almannai, M., Dai, H., El-Hattab, A. W., Wong, L. J. C. (2017). “FBXL4-
related encephalomyopathic mitochondrial DNA depletion syndrome,” in
GeneReviewsr, eds R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A.
Amemiya, L. J. H. Bean, T. D. Bird, N. Ledbetter, H. C. Mefford, R. J. H. Smith,
and K. Stephens (Seattle, WA: University of Washington). Available online at:
http://www.ncbi.nlm.nih.gov/books/NBK425540/
Antoun, G., McBride, S., Vanstone, J. R., Naas, T., Michaud, J., Redpath, S.,
et al. (2016). Detailed biochemical and bioenergetic characterization of FBXL4-
related encephalomyopathic mitochondrial DNA depletion. JIMD Rep. 27, 1–9.
doi: 10.1007/8904_2015_491
Bai, C., Sen, P., Hofmann, K., Ma, L., Goebl, M., Harper, J. W., et al. (1996). SKP1
Connects Cell Cycle Regulators to the Ubiquitin ProteolysisMachinery through
a Novel Motif, the F-Box. Cell 86, 263–274.
Barøy, T., Pedurupillay, C. R., Bliksrud, Y. T., Rasmussen, M., Holmgren, A.,
Vigeland, M. D., et al. (2016). A novel mutation in FBXL4 in a Norwegian child
with encephalomyopathic mitochondrial DNA depletion syndrome 13. Eur. J.
Med. Genet. 59, 342–346. doi: 10.1016/j.ejmg.2016.05.00
Bonnen, P. E., Yarham, J. W., Besse, A., Wu, P., Faqeih, E. A., Al-Asmari, A. M.,
et al. (2013). Mutations in FBXL4 cause mitochondrial encephalopathy and a
disorder of mitochondrial DNAmaintenance. Am. J. Hum. Genet. 93, 471–481.
doi: 10.1016/j.ajhg.2013.07.017
Cenciarelli, C., Chiaur, D. S., Guardavaccaro, D., Parks, W., Vidal, M., and Pagano,
M. (1999). Identification of a family of human F-box proteins. Curr. Biol. 9,
1177–9.
Chen, H., Vermulst, M., Wang, Y. E., Chomyn, A., Prolla, T. A., McCaffery,
J. M., et al. (2010). Mitochondrial fusion is required for mtDNA stability
in skeletal muscle and tolerance of mtDNA mutations. Cell 141, 280–289.
doi: 10.1016/j.cell.2010.02.026
Dai, H., Zhang, V.W., El-Hattab, A.W., Ficicioglu, C., Shinawi, M., Lines, M., et al.
(2017). FBXL4 defects are common in patients with congenital lactic acidemia
and encephalomyopathicmitochondrial DNAdepletion syndrome.Clin. Genet.
91, 634–639. doi: 10.1111/cge.12894
El-Hattab, A. W., Craigen, W. J., and Scaglia, F. (2017b). Mitochondrial
DNA maintenance defects. Biochim. Biophys. Acta 1863, 1539–1555.
doi: 10.1016/j.bbadis.2017.02.017
El-Hattab, A. W., Dai, H., Almannai, M., Wang, J., Faqeih, E. A., Al Asmari, A.,
et al. (2017a). Molecular and clinical spectra of FBXL4 deficiency. Hum. Mutat.
38, 1649–1659. doi: 10.1002/humu.23341
Gai, X., Ghezzi, D., Johnson, M. A., Biagosch, C. A., Shamseldin, H. E., Haack,
T. B., et al. (2013). Mutations in FBXL4, encoding a mitochondrial protein,
Frontiers in Genetics | www.frontiersin.org 7 February 2019 | Volume 10 | Article 39
Ballout et al. FBXL4 Deficiency and Mitochondrial Disorders
cause early-onset mitochondrial encephalomyopathy. Am. J. Hum. Genet. 93,
482–495. doi: 10.1016/j.ajhg.2013.07.016
Huemer, M., Karall, D., Schossig, A., Abdenur, J. E., Al Jasmi, F., Biagosch, C., et al.
(2015). Clinical, morphological, biochemical, imaging and outcome parameters
in 21 individuals with mitochondrial maintenance defect related to FBXL4
mutations. J. Inherit. Metab. Dis. 38, 905–914. doi: 10.1007/s10545-015-9836-6
Inhorn, M. C., Kobeissi, L., Nassar, Z., Lakkis, D., Fakih, M. H.,Inhorn, M. C.,
et al. (2009). Consanguinity and family clustering of male factor infertility in
Lebanon. Fertil. Steril. 91, 1104–1109. doi: 10.1016/j.fertnstert.2008.01.008
Li, Q., Li, Y., Wang, X., Qi, J., Jin, X., Tong, H., et al. (2017). Fbxl4 serves
as a clock output molecule that regulates sleep through promotion of
rhythmic degradation of the GABAA receptor. Curr. Biol. 27, 3616–3625 e5.
doi: 10.1016/j.cub.2017.10.052
Morton, S. U., Neilan, E. G., Peake, R. W. A., Shi, J., Schmitz-Abe, K., Towne, M.,
et al. (2016). Hyperammonemia as a Presenting Feature in Two Siblings with
FBXL4 Variants. JIMD Rep. 35, 7–15. doi: 10.1007/8904_2016_17
Orth,M., Handley, O. J., Schwenke, C., Dunnett, S. B., Craufurd, D., Ho, A. K., et al.
(2010). Observing Huntington’s Disease: the European Huntington’s Disease
Network’s REGISTRY. PLoS Curr. 2:RRN1184. doi: 10.1371/currents.RR
N1184
Pronicka, E., Piekutowska-Abramczuk, D., Ciara, E., Trubicka, J., Rokicki,
D., Karkucinska-Wieckowska, A., et al. (2016). New perspective in
diagnostics of mitochondrial disorders: two years’ experience with whole-
exome sequencing at a national paediatric centre. J. Transl. Med. 14:174.
doi: 10.1186/s12967-016-0930-9
Shamseldin, H. E., Alshammari, M., Al-Sheddi, T., Salih, M. A., Alkhalidi, H.,
Kentab, A., et al. (2012). Genomic analysis of mitochondrial diseases in a
consanguineous population reveals novel candidate disease genes. J. Med.
Genet. 49, 234–241. doi: 10.1136/jmedgenet-2012-100836
Stankiewicz, E., Mao, X., Mangham, D. C., Xu, L., Yeste-Velasco, M., Fisher, G.,
et al. (2017). Identification of FBXL4 as a metastasis associated gene in prostate
cancer. Sci. Rep. 7:5124. doi: 10.1038/s41598-017-05209-z
Tadmouri, G. O., Nair, P., Obeid, T., Al Ali, M. T., Al Khaja, N., and Hamamy,
H. A. (2009). Consanguinity and reproductive health among Arabs. Reprod.
Health 6:17. doi: 10.1186/1742-4755-6-17
van Rij, M. C., Jansen, F. A., Hellebrekers, D. M., Onkenhout, W., Smeets, H.
J., Hendrickx, A. T., et al. (2016). Polyhydramnios and cerebellar atrophy:
a prenatal presentation of mitochondrial encephalomyopathy caused by
mutations in the FBXL4 gene. Clin. Case Rep. 4, 425–428. doi: 10.1002/ccr3.511
Viscomi, C., and Zeviani, M. (2017). MtDNA-maintenance defects: syndromes and
genes. J. Inherit. Metab. Dis. 40, 587–599. doi: 10.1007/s10545-017-0027-5
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., and Harper, J.
W. (1999). The SCFbeta-TRCP-ubiquitin ligase complex associates specifically
with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and
stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13, 270–283.
Wortmann, S. B., Koolen, D. A., Smeitink, J. A., van den Heuvel, L.,
and Rodenburg, R. J. (2015). Whole exome sequencing of suspected
mitochondrial patients in clinical practice. J. Inherit. Metab. Dis. 38, 437–443.
doi: 10.1007/s10545-015-9823-y
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer DG declared a past co-authorship with one of the authors PB
to the handling editor.
Copyright © 2019 Ballout, Al Alam, Bonnen, Huemer, El-Hattab and Shbarou.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Genetics | www.frontiersin.org 8 February 2019 | Volume 10 | Article 39
